Gareth Hughes

8.0k total citations · 1 hit paper
34 papers, 1.5k citations indexed

About

Gareth Hughes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Gareth Hughes has authored 34 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 7 papers in Epidemiology. Recurrent topics in Gareth Hughes's work include Advanced Breast Cancer Therapies (9 papers), Pituitary Gland Disorders and Treatments (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). Gareth Hughes is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), Pituitary Gland Disorders and Treatments (6 papers) and Neuroendocrine Tumor Research Advances (5 papers). Gareth Hughes collaborates with scholars based in United States, United Kingdom and Switzerland. Gareth Hughes's co-authors include Kanti V. Mardia, Sara A. Hurvitz, Charles Taylor, Aditya Bardia, Fábio Franke, Nadia Harbeck, Marco Colleoni, Debu Tripathy, Yen‐Shen Lu and Joohyuk Sohn and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Gareth Hughes

33 papers receiving 1.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

2019 591 citations Seock‐Ah Im, Yen‐Shen Lu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gareth Hughes United States	16	775	677	281	270	262	34	1.5k
Akira Ono Japan	29	1.9k 2.4×	1.7k 2.6×	393 1.4×	423 1.6×	113 0.4×	183	2.9k
Sukhmani K. Padda United States	21	640 0.8×	724 1.1×	181 0.6×	139 0.5×	126 0.5×	94	1.5k
Shengxiang Rao China	32	637 0.8×	966 1.4×	251 0.9×	868 3.2×	192 0.7×	173	3.6k
Huy Gia Vuong United States	25	307 0.4×	273 0.4×	172 0.6×	188 0.7×	854 3.3×	83	1.7k
Susan Fineberg United States	22	210 0.3×	636 0.9×	494 1.8×	104 0.4×	253 1.0×	61	1.6k
David B. Mansur United States	21	421 0.5×	210 0.3×	205 0.7×	283 1.0×	97 0.4×	82	1.5k
Kazuhiro Araki Japan	20	543 0.7×	695 1.0×	205 0.7×	105 0.4×	77 0.3×	87	1.4k
Νικόλαος Παπαθανασίου Greece	16	221 0.3×	326 0.5×	130 0.5×	347 1.3×	94 0.4×	51	1.3k
Nicholas F. Marko United States	21	390 0.5×	161 0.2×	100 0.4×	273 1.0×	171 0.7×	49	1.3k
Megu Ohtaki Japan	20	419 0.5×	109 0.2×	178 0.6×	134 0.5×	102 0.4×	94	1.7k

Countries citing papers authored by Gareth Hughes

Since Specialization

Citations

This map shows the geographic impact of Gareth Hughes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gareth Hughes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gareth Hughes more than expected).

Fields of papers citing papers by Gareth Hughes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gareth Hughes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gareth Hughes. The network helps show where Gareth Hughes may publish in the future.

Co-authorship network of co-authors of Gareth Hughes

This figure shows the co-authorship network connecting the top 25 collaborators of Gareth Hughes. A scholar is included among the top collaborators of Gareth Hughes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gareth Hughes. Gareth Hughes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hughes, Gareth, et al.. (2024). Enteric fever in a non-endemic setting: Review of cases over a 12-year period at University hospitals Birmingham, UK. Clinical Infection in Practice. 24. 100380–100380.

Hughes, Gareth, Ed Moran, & Martin Dedicoat. (2019). Encephalitis secondary to nitrous oxide and vitamin B₁₂ deficiency. BMJ Case Reports. 12(12). e229380–e229380. 2 indexed citations

Hurvitz, Sara A., Seock‐Ah Im, Yen‐Shen Lu, et al.. (2019). Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.. Journal of Clinical Oncology. 37(18_suppl). LBA1008–LBA1008. 21 indexed citations

Harbeck, Nadia, Rafael Villanueva-Vázquez, Debu Tripathy, et al.. (2018). Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptorpositive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial. European Journal of Cancer. 92. S3–S3. 1 indexed citations

Hughes, Gareth, et al.. (2017). The role of Hi Fidelity simulation in designing emergency airway management algorithms: The experience of the UK National Tracheostomy Safety Project.. Research Explorer (The University of Manchester). 1 indexed citations

Hughes, Gareth, Michael G. Crooks, Ian Forrest, et al.. (2017). Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clinical and Translational Medicine. 6(1). 41–41. 33 indexed citations

McGrath, Brendan, et al.. (2017). The role of high-fidelity simulation in designing emergency airway management algorithms: the experience of the UK National Tracheostomy safety project. BMJ Simulation & Technology Enhanced Learning. 5(2). 118–120. 2 indexed citations

Hughes, Gareth, et al.. (2016). Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine. 5(9). 78–78. 137 indexed citations

Tripathy, Debu, Aditya Bardia, Sara A. Hurvitz, et al.. (2015). Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7.. Journal of Clinical Oncology. 33. 6 indexed citations

10.

Im, Seock‐Ah, Louis WC Chow, Zhi‐Ming Shao, et al.. (2015). 116TiP MONALEESA-7: a phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) combined with standard first-line endocrine therapy (ET) for the treatment of premenopausal women with HR +, HER2– advanced breast cancer (aBC). Annals of Oncology. 26. ix16–ix16. 1 indexed citations

11.

Pivonello, Rosario, Stephan Petersenn, John Newell‐Price, et al.. (2014). Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. Clinical Endocrinology. 81(3). 408–417. 84 indexed citations

12.

Schopohl, Jochen, Feng Gu, R.D. Rubens, et al.. (2014). Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary. 18(5). 604–612. 47 indexed citations

13.

Petersenn, Stephan, Jens Bollerslev, Ayman M. Arafat, et al.. (2014). Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study. The Journal of Clinical Pharmacology. 54(11). 1308–1317. 23 indexed citations

14.

Petersenn, Stephan, Andrew J. Farrall, Christophe De Block, et al.. (2013). Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary. 17(2). 132–140. 42 indexed citations

15.

Wolin, Edward M., et al.. (2013). Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemotherapy and Pharmacology. 72(2). 387–395. 34 indexed citations

16.

Boscaro, Marco, Jérôme Bertherat, James W. Findling, et al.. (2013). Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study. Pituitary. 17(4). 320–326. 42 indexed citations

17.

Kvols, Larry K., Kjell E. Öberg, Thomas M. O’Dorisio, et al.. (2012). Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine Related Cancer. 19(5). 657–666. 152 indexed citations

18.

Mardia, Kanti V., Gareth Hughes, Charles Taylor, & Harshinder Singh. (2008). A multivariate von mises distribution with applications to bioinformatics. Canadian Journal of Statistics. 36(1). 99–109. 99 indexed citations

19.

Hughes, Gareth, et al.. (2001). FRI0070 Safety and tolerability of a rapid infusion of remicade (infliximab) in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases. 60. A474–A474. 1 indexed citations

20.

Hughes, Gareth, et al.. (1999). Use of human patient simulation to teach emergency medicine trainees advanced airway skills.. Emergency Medicine Journal. 16(6). 395–399. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact